Therefore, correction of hypophosphatemia in the face of residual FGF23 elevations is insufficient to correct the bone phenotype associated with ARHR in the long term and the residual bone phenotype might be due to persistent FGF23 elevations and/or DMP1 deficiency. This evidence concerns the gene FGF23 and hyperinsulinemic hypoglycemia, familial, 4.